DarioHealth Corp. DRIO
- Market cap
- $66.3M
- P/E
- 0.0×
Follow DRIO
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.42 | 26.60 | 13.12 | 4.00 | 60.40 | 200.40 | 70.60 | 13.60 | 12.62 | 5.94 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 3,491.97 | 94.00 | 43.00 | 225.00 | 449.80 | 637.00 | 274.20 | 135.60 | 52.00 | 31.00 |
High Price
|
|||
| 31 | 48 | 76 | 72 | 139 | 214 | 252 | 294 | 202 | 165 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 3 | 5 | 7 | 8 | 8 | 21 | 28 | 20 | 27 | 22 |
Revenue
|
|||
| (29.61%) | 25.36% | 23.87% | 34.36% | 33.17% | 19.32% | 34.91% | 29.40% | 49.06% | 56.64% |
Gross Margin
|
|||
| (11) | (16) | (18) | (18) | (29) | (77) | (62) | (59) | (45) | (42) |
EBT
|
|||
| (388.41%) | (304.51%) | (240.78%) | (234.63%) | (388.66%) | (374.05%) | (224.87%) | (291.68%) | (164.94%) | (186.10%) |
EBT Margin
|
|||
| (11) | (16) | (18) | (18) | (29) | (77) | (62) | (59) | (43) | (42) |
Net Income
|
|||
| 0 | 0 | 0 | 0 | 0 | 4 | 5 | 5 | 7 | 3 |
Depreciation
|
|||
| 215.62 | 214.52 | 126.18 | 66.72 | 25.41 | 24.73 | 23.40 | 14.35 | 11.03 | 5.61 |
Revenue/Sh
|
|||
| (836.00) | (656.00) | (312.00) | (160.00) | (98.76) | (81.40) | (50.80) | (38.60) | (17.43) | (10.12) |
Earnings/Sh
|
|||
| (644.54) | (440.62) | (195.73) | (138.79) | (59.48) | (60.76) | (40.48) | (21.41) | (15.73) | (6.51) |
Cash Flow/Sh
|
|||
| (62.15) | (8.09) | (1.21) | (0.86) | (0.40) | (0.31) | (0.48) | (0.41) | (0.06) | (0.04) |
Capex/Sh
|
|||
| (706.69) | (448.71) | (196.95) | (139.66) | (59.87) | (61.08) | (40.97) | (21.83) | (15.78) | (6.55) |
Free CF/Sh
|
|||
| (503.15) | 163.53 | 152.30 | 166.76 | 94.40 | 103.12 | 67.69 | 40.99 | 29.37 | 17.05 |
Book Value/Sh
|
|||
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 4 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.29 | 0.15 | 0.12 | 1.97 | 11.25 | 10.49 | 3.72 | 2.36 | 1.43 | 2.03 |
PS Ratio
|
|||
| 0.00 | 0.20 | 0.10 | 0.79 | 3.03 | 2.52 | 1.29 | 0.82 | 0.54 | 0.67 |
PB Ratio
|
|||
| (0.18) | (0.62) | (1.39) | (0.65) | 7.52 | 8.75 | 2.90 | 1.94 | 1.44 | 2.69 |
EV/Sales
|
|||
| 0.05 | 0.29 | 0.89 | 0.31 | (3.19) | (3.54) | (1.65) | (1.26) | (0.99) | (2.27) |
EV/FCF
|
|||
| (8) | (11) | (11) | (16) | (18) | (50) | (48) | (30) | (39) | (26) |
Op' Cash Flow
|
|||
| (1) | 0 | 0 | 0 | 0 | 0 | (1) | (1) | 0 | 0 |
Capex
|
|||
| (9) | (11) | (12) | (16) | (18) | (51) | (48) | (31) | (39) | (26) |
FCF
|
|||
| 0 | 3 | 8 | 18 | 27 | 31 | 46 | 35 | 24 | 26 |
Working Cap'
|
|||
| — | — | — | 1 | 1 | 0 | 27 | 29 | 29 | 31 |
Total Debt
|
|||
| (1) | (4) | (11) | (20) | (28) | (36) | (23) | (9) | 0 | 5 |
Net Debt
|
|||
| (7) | 4 | 9 | 19 | 28 | 86 | 80 | 58 | 72 | 68 |
Sh' Equity
|
|||
| (259.40%) | (295.47%) | (173.87%) | (108.08%) | (110.39%) | (115.68%) | (58.04%) | (58.92%) | (38.07%) | (53.93%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (95.93%) | (61.85%) | (70.80%) | (49.91%) | (31.63%) |
ROIC
|
|||
| 285.85% | 1,230.62% | (284.41%) | (150.19%) | (140.73%) | (138.55%) | (77.12%) | (91.95%) | (62.97%) | (88.23%) |
ROE
|
|||
DarioHealth Corp. peers in Health Information Services
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CCLD CareCloud, Inc. | $87.5M | 29.4× | Compare |
| ONMD OneMedNet Corporation | $41.8M | 0.0× | Compare |
| HCAT Health Catalyst, Inc. | $131.0M | 0.0× | Compare |
| LFMD LifeMD, Inc. | $140.3M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DH Definitive Healthcare Corp. | $146.3M | 0.0× | Compare |
| OPRX OptimizeRx Corp. | $148.6M | 33.4× | Compare |
| BEAT HeartBeam, Inc. | $21.7M | 0.0× | Compare |
| SPOK Spok Holdings, Inc. | $216.5M | 17.4× | Compare |
DarioHealth Corp. (DRIO) key facts
- DarioHealth Corp. (DRIO) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- DarioHealth Corp.’s revenue for fiscal 2025 (year ended December 2025) was $22.4 million, down 17.3% from fiscal 2024.
- As of September 25, 2026, DRIO traded at $6.63, a market capitalization of $66.3 million.
- Return on equity was −88.2% and debt-to-equity 0.56.
DarioHealth Corp. (DRIO) Latest News
17 Sep
DarioHealth wins contract with one of New Jersey's largest health plans covering 1.5 million lives. Contract win expands reach to 1.5 million covered lives and drives material revenue growth.
11 Aug
DarioHealth Corp's Q2 2026 earnings call highlighted the multi-condition platform as a primary growth driver for the company. Multi-condition platform focus signals major strategic expansion with potential to significantly boost revenue and competitive positioning.
DarioHealth Corp. (DRIO) held its Q2 2026 earnings call, presenting quarterly financial results, operational updates and forward outlook for the diabetes management solutions provider. Quarterly earnings data and guidance typically affect near-term stock sentiment and valuation without altering long-term company direction.
DarioHealth Corp. held its Q2 2026 earnings call covering quarterly financial results, business updates and forward outlook. Earnings call delivers financial metrics and guidance that can shift near-term investor sentiment and stock trading.
DarioHealth Q2 earnings call highlighted financial performance, revenue figures, user growth metrics and company strategic outlook. Q2 earnings updates deliver moderate influence on financial performance and investor sentiment for DRIO.
DarioHealth Corp. (DRIO) released its second quarter 2026 financial results. Quarterly earnings reports can shift short-term investor views and trading activity for DarioHealth.
4 Aug
DarioHealth expands its provider-backed cardiometabolic platform with new women's health and sleep solutions to meet client demand. Platform expansion with new solutions supports business growth and client alignment.
30 Jul
DarioHealth launches integrated GLP-1 program merging its digital chronic care platform with provider-backed clinical care into single end-to-end experience. GLP-1 program launch marks major strategic expansion into high-demand chronic care market with potential to alter company trajectory.
16 Jul
Fortune 50 employer awards DarioHealth Corp. contract to deliver AI-powered cardiometabolic care platform. Major contract win from large employer expands revenue and market reach for DarioHealth.
Fortune 50 employer awards DarioHealth contract to deliver AI-powered cardiometabolic care platform. Major contract win from Fortune 50 employer signals substantial revenue growth and market expansion for DarioHealth.
13 Jul
DarioHealth Corp. anticipates its proprietary AI engine DarioIQ™ will increase recurring revenue from existing customers by 10-15%. Projected 10-15% recurring revenue growth from AI engine signals major upside for financial trajectory and investor outlook.
6 Jul
DarioHealth Corp. signed a new agreement with a major Arizona health insurer representing hundreds of thousands of lives through its Amwell partnership. New agreement expands DarioHealth reach to hundreds of thousands of lives via major Arizona insurer partnership.
2 Jul
Top national health plan extends DarioHealth mental health agreement and expands partnership into cardiometabolic care under multi-condition growth strategy. Major health plan partnership extension plus cardiometabolic expansion signals significant revenue growth and market traction for DarioHealth.
29 Jun
DarioHealth Corp. announces strategic collaboration with Beluga Health to deliver provider-backed, integrated care at scale. Strategic collaboration expands DarioHealth provider network and integrated care delivery capabilities.
17 Jun
DarioHealth Corp. (DRIO) received an analyst upgrade to Buy rating based on improved outlook and operational factors. Stock rating upgrade can lift near-term sentiment and share price but leaves underlying business trajectory unchanged.
8 Jun
DarioHealth presented four studies at the American Diabetes Association Scientific Sessions demonstrating the commercial and clinical value of its digital health platform. Conference study presentations provide clinical validation that can modestly improve market sentiment and positioning for DarioHealth.
26 May
DarioHealth expands hypertension program in Solera Health network, more than doubling addressable market to over 500,000 eligible lives. Expansion to over 500,000 lives materially increases addressable market and revenue potential.
14 May
DarioHealth Corp. released Q1 2026 earnings call summary covering financial results and business updates. Q1 earnings call delivers financial metrics and guidance that moderately shape near-term stock sentiment and operational outlook.
13 May
DarioHealth Corp. (DRIO) Q1 2026 earnings call highlights emphasize navigating growth amid strategic initiatives. Earnings highlights on growth navigation and strategic moves indicate significant influence on DRIO's trajectory and investor sentiment.
DarioHealth Corp. (DRIO) released Q1 earnings call highlights detailing financial results, operational progress, and future outlook. Q1 earnings call highlights cover financial performance and strategic updates that significantly influence investor sentiment and stock trajectory.
DarioHealth Corp. (DRIO) released Q1 2026 earnings results including the full earnings call transcript. Q1 2026 earnings results and call details directly impact financial performance, guidance, and investor sentiment for DRIO.
DarioHealth Corp. (DRIO) reported first quarter 2026 financial and operating results. Quarterly earnings reports like this directly affect financial performance metrics and investor sentiment toward the company's trajectory.
DarioHealth Corp. (DRIO) reported a first-quarter loss but beat revenue estimates. Q1 revenue beat despite loss moderately affects financial performance and market sentiment.
29 Apr
DarioHealth President Steven Nelson discussed AI applications in chronic care management alongside company strategies for expansion and performance gains leading into 2026. Executive comments on AI-driven chronic care and 2026 growth targets signal major strategic and technological shifts likely to influence DarioHealth's market trajectory.
20 Apr
DarioHealth Corp. (DRIO) published a real-world study in JMIR Formative Research showing its digital behavioral health program improves workplace function and productivity outcomes. Peer-reviewed real-world evidence validates the digital program's efficacy, moderately enhancing credibility and market positioning.
13 Apr
DarioHealth Corp. (DRIO) appoints veteran healthcare executive John R. Palumbo to its Board of Directors to support accelerated commercial scaling. Adding a veteran healthcare executive to the board bolsters leadership for commercial scaling, moderately influencing growth and market positioning.
24 Mar
DarioHealth Corp. (DRIO) shifts its narrative through new research targets and intensified GLP-1 focus, positioning for growth in diabetes and metabolic health amid evolving market dynamics. New research targets and GLP-1 emphasis mark major strategic moves into high-growth weight management and diabetes markets, likely boosting investor sentiment and competitive edge.
19 Mar
DarioHealth Corp. released Q4 2025 earnings call summary highlighting financial results, operational updates, and forward guidance. Q4 earnings call summaries disclose key financial metrics and strategic plans that significantly influence market performance and investor outlook.
DarioHealth Corp. (DRIO) released Q4 2025 earnings call transcript detailing financial results, operational updates, and forward guidance. Q4 earnings transcript discloses key financial metrics, growth strategies, and outlook that can significantly sway stock performance and investor confidence.
DarioHealth Corp (DRIO) Q4 2025 earnings call highlights strategic growth initiatives amid persistent revenue challenges. Earnings highlights detail strategic growth offsetting revenue shortfalls, moderately affecting financial performance and investor sentiment.